Pfizer: recruitment completed for VALOR trial
(CercleFinance.com) - Pfizer and Valneva announce the completion of enrolment in the VALOR Phase III study of their Lyme disease vaccine candidate, VLA15, a trial designed to confirm the product's efficacy, safety, batch homogeneity and immunogenicity.
Launched in August 2022, the trial enrolled 9,437 participants aged five and over in North America and Europe. It is due to be completed by the end of 2025. For the record, Pfizer and Valneva signed a collaboration agreement in April 2020 to jointly develop VLA15.
The VLA15 candidate has demonstrated a strong immune response and has been considered generally safe and well tolerated in all age groups in preclinical and clinical studies conducted to date, the pharmaceutical groups said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.